eFFECTOR Therapeutics, Inc.
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04632381
- Locations
- 🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT04622007
- Locations
- 🇺🇸
Texas Oncology - Memorial City, Houston, Texas, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Ventura - UCLA, Ventura, California, United States
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04092673
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT03690141
- Locations
- 🇺🇸
Kimmel Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸University of Washington, Seattle, Washington, United States
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT03616834
- Locations
- 🇺🇸
University of Arizona - Cancer Center, Tucson, Arizona, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03318562
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Kansas City Research Institute, Kansas City, Missouri, United States
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT03258398
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT02937675
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Florida Cancer Specialist, Sarasota, Florida, United States
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 66
- Registration Number
- NCT02605083
- Locations
- 🇺🇸
SCRI at HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States